The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease.
- Author:
Hyun Jung YU
1
;
Seong Ho KOH
Author Information
- Publication Type:Review
- Keywords: Alzheimer's disease; Phosphatidylinositol 3-kinase; AKT; Amyloid beta; Tau
- MeSH: Alzheimer Disease*; Amyloid; Dementia; Phosphatidylinositol 3-Kinase; Tauopathies
- From:Hanyang Medical Reviews 2017;37(1):18-24
- CountryRepublic of Korea
- Language:English
- Abstract: Alzheimer's disease (AD) is the most common form of dementia. Although uncountable clinical trials have been done to develop the treatment of AD, there are a couple of drugs that can be used only for symptomatic treatment. Therefore, many studies based on the amyloid cascade hypothesis and the tauopathy hypothesis are still ongoing. After the failure of numerous huge Phase III clinical trials, arguments on those hypotheses have arisen and efforts to establish other possible therapeutic strategies based on diverse plausible mechanisms associated with AD have been done as well. One of the new therapeutic targets for AD is the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. In this review, questions on the two hypotheses, the definition of the PI3K/AKT pathway, the relationship between the pathway and AD, and the possibility of the modulation of the pathway as a new therapeutic strategy for AD will be discussed briefly.
